natgillin/translations-raw huggingface dataset:
Pregnancy and breast-feeding Do not use Comtess during pregnancy or if you are breast-feeding.
Nosečnost in dojenje Ne jemljite zdravila Comtess v nosečnosti ali če dojite.
Driving and using machines Comtess taken together with levodopa may lower your blood pressure, which may make you feel light-headed or dizzy.
Vpliv na sposobnost upravljanja vozil in strojev Comtess, ki ga jemljete skupaj z levodopo, vam lahko zniža krvni tlak, zaradi česar lahko postanete omotični ali vrtoglavi.
Comtess taken with levodopa may make you feel very drowsy, or cause you to sometimes find yourself suddenly falling asleep.
Comtess, ki ga vzamete skupaj z levodopo, lahko povzroči hudo zaspanost ali povzroči, da včasih nenadoma zaspite.
HOW TO TAKE COMTESS
KAKO JEMATI ZDRAVILO COMTESS
Always take Comtess exactly as your doctor has told you.
Pri jemanju zdravila Comtess natančno upoštevajte zdravnikova navodila.
Comtess is taken together with preparations containing levodopa (either levodopa/ carbidopa preparations or levodopa/ benserazide preparations).
Comtess se jemlje skupaj z zdravili, ki vsebujejo levodopo (bodisi pripravki levodope/ karbidope bodisi pripravki levodope/ benserazida).
The usual dose of Comtess is one 200 mg tablet with each levodopa dose.
Običajni odmerek zdravila Comtess je ena 200- miligramska tableta z vsakim odmerkom levodope.
2,000 mg of Comtess.
2. 000 mg Comtessa.
If you take more Comtess than you should In the event of an overdose, consult your doctor or the nearest hospital immediately.
Če ste vzeli večji odmerek zdravila Comtess, kot bi smeli Če ste vzeli prevelik odmerek, se takoj posvetujte s svojim zdravnikom ali najbližjo bolnišnico.
If you forget to take Comtess If you forget to take the Comtess tablet with your levodopa dose, you should continue the treatment by taking the next Comtess tablet with your next levodopa dose.
Če ste pozabili vzeti zdravilo Comtess Če pozabite vzeti tableto Comtessa s svojim odmerkom levodope, nadaljujte zdravljenje tako, da vzamete naslednjo tableto Comtessa z naslednjim odmerkom levodope.
18 If you stop taking Comtess Do not stop taking Comtess unless your doctor tells you to.
Če ste prenehali jemati zdravilo Comtess Ne prekinite jemanja Comtessa, razen če vam to naroči vaš zdravnik.
In such a case your doctor may need to re-adjust the dosage of your other antiparkinsonian medicines.
V takem primeru vam bo zdravnik mogoče prilagodil odmerjanje vaših drugih antiparkinsonskih zdravil.
Abrupt discontinuation of both Comtess and other antiparkinsonian medicines may result in unwanted side effects.
Nenadna prekinitev zdravljenja s Comtessom in drugimi antiparkinsonskimi zdravili lahko povzroči neželene učinke.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
19 Če imate dodatna vprašanja o uporabi zdravila, se posvetujte z zdravnikom ali s farmacevtom.
Like all medicines, Comtess can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Comtess neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Usually side effects caused by Comtess are mild to moderate.
Neželeni učinki, ki jih povzroča Comtess, so navadno blagi do zmerni.
Very common (affects more than 1 patient in 10) Common (affects 1 to 10 patients in 100) Uncommon (affects 1 to 10 patients in 1,000) Rare (affects 1 to 10 patients in 10,000) Very rare (affects less than 1 patient in 10,000) Not known (frequency cannot be estimated from the available data).
Zelo pogosti (pojavijo se pri več kot 1 bolniku od 10) Pogosti (pojavijo se pri 1 do 10 bolnikih od 100) Občasni (pojavijo se pri 1 do 10 bolnikih od 1. 000) Redki (pojavijo se pri 1 do 10 bolnikih od 10. 000) Zelo redki (pojavijo se pri manj kot 1 bolniku od 10. 000) Neznana (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov)
The exact frequencies of these side effects are not known but are based on reports received since the product has been on the market: colitis (inflammation of the colon), hepatitis and skin, hair, beard and nail discolorations.
Natančna pogostnost naslednjih neželenih učinkov ni znana, podatki temeljijo na poročilih iz obdobja, odkar je zdravilo dostopno na trgu: kolitis (vnetje debelega črevesa), hepatitis (vnetje jeter) in sprememba barve kože, las, brade in nohtov.
If you experience such effects at the start of treatment with Comtess you should contact your doctor, who may decide to adjust your dosage of levodopa.
Če opazite take učinke na začetku zdravljenja s Comtessom, se morate posvetovati s svojim zdravnikom, ki vam bo mogoče prilagodil odmerjanje levodope.
Excessive daytime drowsiness has been reported in rare cases in patients receiving Comtess with levodopa and there have been isolated cases of sudden sleep onset episodes.
V redkih primerih pri bolnikih, ki jemljejo Comtess z levodopo, poročajo o čezmerni zaspanosti podnevi, v posameznih primerih pa o nenadnih napadih spanja.
NMS is a rare severe reaction to medicines used to treat disorders of the central nervous system and characterised by stiffness, muscle twitching, shaking, mental changes, coma, high body temperature, increased heart rate, and unstable blood pressure.
Nevroleptični maligni sindrom je redka huda reakcija na zdravila za zdravljenje centralnega živčnega sistema, za katero so značilni okorelost, trzanje mišic, tresenje, spremembe duševnega stanja, koma, zvišana telesna temperatura, pospešen utrip srca in nestabilen krvni tlak.
Rhabdomyolysis is a rare severe muscle disorder.
Rabdomioliza je redka huda bolezen mišic.
19 Behavioural changes such as urge to gamble (pathological gambling) or increased sexual desire and urges (increased libido and hypersexuality) have been reported in patients receiving dopaminergic medicines including Comtess with levodopa.
Pri bolnikih, ki so prejemali dopaminergična zdravila, ki vključujejo Comtess z levodopo, so opisovali spremembe vedenja, kot so potreba po igranju iger na srečo (patološko hazardiranje) ali povečana spolna sla in pretirana potreba po spolnosti (povečan libido in hiperseksualnost).
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.
20 Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželen učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika.
HOW TO STORE COMTESS
SHRANJEVANJE ZDRAVILA COMTESS
Do not use Comtess after the expiry date which is stated on the carton and on the bottle label.
Zdravila Comtess ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in nalepki stekleničke.
What Comtess contains
Kaj vsebuje zdravilo Comtess
- The other ingredients in the tablet core are microcrystalline cellulose, croscarmellose sodium,
- Pomožne snovi v jedru tablete so mikrokristalna celuloza, premreženi natrijev karmelozat,
povidone and magnesium stearate.
povidon in magnezijev stearat.
- The film-coating contains partly hydrolysed polyvinyl alcohol, talc, macrogol, soybean lecithin,
- Filmska obloga vsebuje delno hidrolizirani polivinil alkohol, smukec, makrogol, sojin lecitin,
What Comtess looks like and contents of the pack Comtess 200 mg film-coated tablets are brownish-orange, oval tablets with "COMT" engraved on one side.
Izgled zdravila in vsebina pakiranja Comtess 200 mg filmsko obložene tablete so rjavkastooranžne, ovalne tablete z vtisnjenim napisom “ COMT ” na eni strani.
Deutschland Orion Pharma GmbH Tel: +49 40 899 689-0
21 Deutschland Orion Pharma GmbH Tel: +49 40 899 689- 0
España Orion Corporation Tel: +358 10 4261
Orion Corporation Tel: +358 10 4261
Κύπρος Orion Corporation Tηλ: +358 10 4261
Suomi/ Finland Orion Corporation Puh. / Tel: +358 10 4261
Sverige Orion Pharma AB Tel: +46 8 623 6440
Sverige Κύπρος Orion Pharma AB Orion Corporation Tel: +46 8 623 6440 Tηλ: +358 10 4261
Detailed information on this medicine is available on the European Medicine’ s Agency (EMEA) web site: http: / /www. emea. europa. eu
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMEA) http: // www. emea. europa. eu
Copalia is a medicine containing two active substances, amlodipine and valsartan.
Copalia je zdravilo, ki vsebuje dve zdravilni učinkovini, amlodipin in valsartan.
It is available as tablets (dark yellow, round:
Zdravilo je na voljo v obliki tablet (temno rumenih okroglih tablet:
5 mg amlodipine and 80 mg valsartan; dark yellow, oval:
5 mg amlodipina in 80 mg valsartana; temno rumenih ovalnih tablet:
5 mg amlodipine and 160 mg valsartan; light yellow, oval:
5 mg amlodipina in 160 mg valsartana; svetlo rumenih ovalnih tablet:
10 mg amlodipine and 160 mg valsartan).
10 mg amlodipina in 160 mg valsartana).
Copalia is used in patients who have essential hypertension (high blood pressure) that is not adequately controlled on either amlodipine or valsartan taken alone. ‘ Essential ’ means that the high blood pressure is not caused by any other condition.
„ Esencialna “ pomeni, da visok krvi tlak ni posledica nobenega drugega bolezenskega stanja.
Copalia is not recommended for use in patients below 18 years of age.
Uporaba zdravila Copalia ni priporočljiva pri bolnikih, mlajših od 18 let.
Copalia is taken by mouth as one tablet once a day with some water, with or without food.
Zdravilo Copalia se zaužije peroralno kot ena tableta na dan z malo vode, skupaj s hrano ali brez nje.
The dose of Copalia to be used depends on the doses of amlodipine or valsartan that the patient was taking before.
Velikost odmerka zdravila Copalia, ki ga je treba vzeti, je odvisna od odmerkov amlodipina ali valsartana, ki ju je bolnik prejemal prej.
The patient may need to take separate tablets or capsules before switching to the combination tablet.
Bolnik bo morda moral pred prehodom na kombinirane tablete nekaj časa jemati dve ločeni vrsti tablet ali kapsul.
Copalia should be used with caution in patients who have problems with their liver or biliary obstructive disorders (problems with the elimination of bile).
Bolniki, ki imajo težave z jetri ali obstruktivno biliarno bolezen (težave z izločanjem žolča), morajo zdravilo Copalia jemati previdno.
Both are anti-hypertensives that have been available separately in the European Union (EU) since the mid-1990s.
Obe sta zdravili proti zvišanemu krvnemu tlaku, ki sta bili v Evropski uniji (EU) na voljo vsako posamično od sredine 90- ih let prejšnjega stoletja.
They act in similar ways to reduce blood pressure by allowing the blood vessels to relax.
Obe na podoben način sproščata napetost žil in tako nižata krvni tlak.
By lowering the blood pressure, the risk caused by high blood pressure, such as having a stroke, is reduced.
Z znižanjem krvnega tlaka se zmanjša tveganje za poškodbe, ki jih povzroča visok krvni tlak, kot je na primer kap.
It blocks special channels on the surface of cells (calcium channels) through which calcium ions normally enter the cells.
Zdravilo zavira posebne kanalčke na površini celic (kalcijevi kanalčki), skozi katere v celico običajno vstopajo kalcijevi ioni.
Valsartan is an ‘ angiotensin II receptor antagonist’, which means that it blocks the action of a hormone in the body called angiotensin II.
Valsartan je antagonist receptorja angiotenzina II, kar pomeni, da zavira delovanje hormona, imenovanega angiotenzin II.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Ker 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. valsartan zaustavi njegovo delovanje z zaviranjem receptorjev, na katere se angiotenzin II običajno veže, hormonu prepreči učinkovanje, zaradi česar se krvne žile lahko razširijo.
Five main studies involving nearly 5,200 patients, mostly with mild to moderate hypertension, were carried out.
Opravili so pet glavnih študij, v katere je bilo vključenih skoraj 5200 bolnikov z blago do zmerno hipertenzijo.
Two studies (involving almost 3,200 patients) compared the effectiveness of amlodipine, valsartan or a combination of both substances with the effectiveness of placebo (a dummy treatment).
V dveh študijah (s skoraj 3200 bolniki) so primerjali učinkovitost amlodipina, valsartana ali kombinacije obeh učinkovin z učinkovitostjo placeba (zdravila brez zdravilne učinkovine).
Two studies (involving 1,891 patients) compared the effects of the combination in patients whose hypertension was not adequately controlled with either 10 mg amlodipine or 160 mg valsartan.
V dveh študijah (s 1891 bolniki) so primerjali učinke kombinacije pri bolnikih, pri katerih 10- miligramski odmerek amlodipina ali 160- miligramski odmerek valsartana nista učinkovito urejala hipertenzije.
The fifth, smaller study compared the effectiveness of the combination with that of lisinopril and hydrochlorothiazide (another combination used to treat hypertension) in 130 patients with severe hypertension.
Peta, manjša študija s 130 bolniki s hudo hipertenzijo je primerjala učinkovitost kombinacije z učinkovitostjo lizinoprila in hidroklorotiazida (drugo kombinacijo zdravil za zdravljenje zvišanega krvnega tlaka).
In all studies, the main measure of effectiveness was the reduction in diastolic blood pressure (the blood pressure measured between two heartbeats).
Glavno merilo učinkovitosti pri vseh študijah je bilo znižanje diastoličnega krvnega tlaka (krvnega tlaka med dvema utripoma srca).
The blood pressure was measured in ‘ millimetres of mercury’ (mmHg).
Krvni tlak so merili v „ milimetrih živega srebra “ (mmHg).
The company also presented evidence that the levels of amlodipine and valsartan in the blood were the same in people taking Copalia and people taking the separate medicines.
Družba je prav tako predložila dokaze o tem, da sta bili ravni amlodipina in valsartana v krvi enaki pri ljudeh, ki so jemali zdravilo Copalia, in ljudeh, ki so jemali obe zdravilni učinkovini ločeno.
The combination of amlodipine and valsartan was more effective at reducing blood pressure than placebo or either valsartan or amlodipine taken alone.
Kombinacija učinkovin amlodipin in valsartan je bila pri nižanju krvnega tlaka učinkovitejša od placeba oziroma zdravljenja samo z valsartanom ali amlodipinom.
In the studies comparing the effectiveness of the combination in patients who were already taking either amlodipine or valsartan, the blood pressure in patients taking valsartan alone had fallen by 6.6 mmHg after eight weeks, compared with 9.6 and 11.4 mmHg in the patients adding 5 or 10 mg amlodipine, respectively.
V študijah, v katerih so primerjali učinkovitost kombinacije pri bolnikih, ki so že jemali amlodipin ali valsartan, je krvni tlak bolnikov, ki so prejemali samo valsartan, po osmih tednih padel za 6, 6 mmHg v primerjavi z 9, 6 in 11, 4 mmHg pri bolnikih, ki so prejemali še dodatnih 5 oziroma 10 mg amlodipina.
Patients taking amlodipine alone had a fall of 10.0 mmHg, compared with 11.8 mmHg in the patients adding 160 mg valsartan.
Tlak bolnikov, ki so jemali le amlodipin, je padel za 10, 0 mmHg v primerjavi z 11, 8 mmHg pri bolnikih, ki so prejemali še dodatnih 160 mg valsartana.
The most common side effects with Copalia (seen in between 1 and 10 patients in 100) are headache, nasopharyngitis (inflammation of the nose and throat), influenza (flu), various types of oedema (swelling), fatigue (tiredness), flushing (reddening), asthenia (weakness) and hot flushes.
Najpogostejši neželeni učinki zdravila Copalia (opaženi pri 1 do 10 bolnikov izmed 100) so glavobol, nazofaringitis (vnetje nosne votline in grla), influenca (gripa), različne vrste edemov (oteklin), utrujenost, pordelost, astenija (oslabelost) in navali vročine.
For the full list of all side effects reported with Copalia, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Copalia, glejte navodilo za uporabo.
Copalia should not be used in patients who may be hypersensitive (allergic) to amlodipine or other medicines in the ‘ dihydropyridine derivatives’ class, to valsartan, or to any of the other ingredients.
Zdravila Copalia ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) amlodipin ali druga zdravila iz razreda „ derivatov dihidropiridina “, valsartan ali katero koli drugo sestavino zdravila.
It must not be used in women who are more than three months pregnant or who are breast-feeding.
Uporabljati ga ne smejo ženske, ki so noseče več kot tri mesece ali ki dojijo.
Its use during the first three months of pregnancy is not recommended.
Njegova uporaba v prvih treh mesecih nosečnosti ni priporočljiva.
Copalia should also not be used in patients who have severe liver, kidney or bile problems, or in patients undergoing dialysis (a blood clearance technique).
Zdravila Copalia prav tako ne smejo jemati bolniki, ki imajo hude težave z jetri, ledvicami ali izločanjem žolča, ali bolniki na dializi (postopek prečiščevanja krvi).
The Committee for Medicinal Products for Human Use (CHMP) decided that Copalia’ s benefits are greater than its risks for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Copalia pri zdravljenju esencialne hipertenzije pri bolnikih, katerih krvnega tlaka ni mogoče ustrezno urejati samo z amlodipinom ali valsartanom, večje od z njim povezanih tveganj.
The Committee recommended that Copalia be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Copalia odobri dovoljenje za promet.
Other information about Copalia:
Druge informacije o zdravilu Copalia:
The European Commission granted a marketing authorisation valid throughout the EU for Copalia to Novartis Europharm Limited on 16 January 2007.
Evropska komisija je dovoljenje za promet z zdravilom Copalia, veljavno po vsej Evropski uniji, odobrila družbi Novartis Europharm Limited dne 16. januarja 2007.
The full EPAR for Copalia can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Copalia je na voljo tukaj.
EU Number EU/ 1/ 06/ 372/ 001 EU/ 1/ 06/ 372/ 002 EU/ 1/ 06/ 372/ 003 EU/ 1/ 06/ 372/ 004 EU/ 1/ 06/ 372/ 005 EU/ 1/ 06/ 372/ 006 EU/ 1/ 06/ 372/ 007 EU/ 1/ 06/ 372/ 008 EU/ 1/ 06/ 372/ 009 EU/ 1/ 06/ 372/ 010 EU/ 1/ 06/ 372/ 011 EU/ 1/ 06/ 372/ 012 EU/ 1/ 06/ 372/ 013 EU/ 1/ 06/ 372/ 014 EU/ 1/ 06/ 372/ 015 EU/ 1/ 06/ 372/ 016 EU/ 1/ 06/ 372/ 017 EU/ 1/ 06/ 372/ 018 EU/ 1/ 06/ 372/ 019 EU/ 1/ 06/ 372/ 020 EU/ 1/ 06/ 372/ 021 EU/ 1/ 06/ 372/ 022 EU/ 1/ 06/ 372/ 023 EU/ 1/ 06/ 372/ 024 EU/ 1/ 06/ 372/ 025 EU/ 1/ 06/ 372/ 026 EU/ 1/ 06/ 372/ 027 EU/ 1/ 06/ 372/ 028 EU/ 1/ 06/ 372/ 029 EU/ 1/ 06/ 372/ 030 EU/ 1/ 06/ 372/ 031 EU/ 1/ 06/ 372/ 032 EU/ 1/ 06/ 372/ 033 EU/ 1/ 06/ 372/ 034 EU/ 1/ 06/ 372/ 035 EU/ 1/ 06/ 372/ 036
Številka EU EU/ 1/ 06/ 372/ 001 EU/ 1/ 06/ 372/ 002 EU/ 1/ 06/ 372/ 003 EU/ 1/ 06/ 372/ 004 EU/ 1/ 06/ 372/ 005 EU/ 1/ 06/ 372/ 006 EU/ 1/ 06/ 372/ 007 EU/ 1/ 06/ 372/ 008 EU/ 1/ 06/ 372/ 009 EU/ 1/ 06/ 372/ 010 EU/ 1/ 06/ 372/ 011 EU/ 1/ 06/ 372/ 012 EU/ 1/ 06/ 372/ 013 EU/ 1/ 06/ 372/ 014 EU/ 1/ 06/ 372/ 015 EU/ 1/ 06/ 372/ 016 EU/ 1/ 06/ 372/ 017 EU/ 1/ 06/ 372/ 018 EU/ 1/ 06/ 372/ 019 EU/ 1/ 06/ 372/ 020 EU/ 1/ 06/ 372/ 021 EU/ 1/ 06/ 372/ 022 EU/ 1/ 06/ 372/ 023 EU/ 1/ 06/ 372/ 024 EU/ 1/ 06/ 372/ 025 EU/ 1/ 06/ 372/ 026 EU/ 1/ 06/ 372/ 027 EU/ 1/ 06/ 372/ 028 EU/ 1/ 06/ 372/ 029 EU/ 1/ 06/ 372/ 030 EU/ 1/ 06/ 372/ 031 EU/ 1/ 06/ 372/ 032 EU/ 1/ 06/ 372/ 033 EU/ 1/ 06/ 372/ 034 EU/ 1/ 06/ 372/ 035 EU/ 1/ 06/ 372/ 036
Invented name Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia
Izmišljeno ime Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia Copalia
Strength 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 160 mg 5 mg/ 160 mg 5 mg/ 160 mg 5 mg/ 160 mg 5 mg/ 160 mg 5 mg/ 160 mg 5 mg/ 160 mg 5 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 160 mg 5 mg/ 160 mg 5 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 5 mg/ 80 mg 5 mg/ 160 mg 10 mg/ 160 mg
jakost 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 160 mg 5 mg/ 160 mg 5 mg/ 160 mg 5 mg/ 160 mg 5 mg/ 160 mg 5 mg/ 160 mg 5 mg/ 160 mg 5 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 160 mg 5 mg/ 160 mg 5 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 5 mg/ 80 mg 5 mg/ 160 mg 10 mg/ 160 mg
Pharmaceutical Form Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet
farmacevtska oblika filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete filmsko obložene tablete
Route of administration Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
pot uporabe peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba